Related Experiment Video
Updated: May 27, 2025
09:05
Minimal Invasive Surgical Procedure of Inducing Myocardial Infarction in Mice
Published on: May 4, 2015
27.5K
Anti-inflammatory Therapies for Ischemic Heart Disease
Tillmann Muhs1, Senka Ljubojevic-Holzer2, Susanne Sattler3,4,5
1Department of Pharmacology, Otto-Loewi Research Center, Medical University of Graz, Neue Stiftingtalstraße 6, 8010, Graz, Austria.
Current Cardiology Reports
|February 19, 2025
Summary
Immunomodulatory therapies targeting the NLRP3 inflammasome show promise for ischemic heart disease (IHD). While effective for chronic conditions like atherosclerosis, acute inflammation post-myocardial infarction (MI) remains challenging.
Area of Science:
- Cardiology
- Immunology
- Molecular Biology
Background:
- Ischemic heart disease (IHD) involves complex inflammatory processes.
- The NLRP3 inflammasome plays a central role in mediating inflammation within the myocardium.
- Emerging immunomodulatory strategies aim to target this pathway for therapeutic benefit.
Purpose of the Study:
- To review current immunomodulatory strategies for ischemic heart disease (IHD).
- To highlight the unifying role of the NLRP3 inflammasome in IHD pathogenesis.
- To discuss the potential and challenges of targeting NLRP3 in various IHD conditions.
Main Methods:
- Review of recent clinical and preclinical trials.
- Analysis of the NLRP3 inflammasome's role in cardiac immune and non-immune cells.
- Examination of specific agents like colchicine, cytokine-based therapies, and SGLT2 inhibitors.
Main Results:
- The NLRP3 inflammasome is crucial in inflammatory signaling across IHD conditions.
- Colchicine, cytokine-based therapies, and SGLT2 inhibitors demonstrate anti-inflammatory effects in IHD.
- Targeting NLRP3 is more effective in chronic inflammation (atherosclerosis, CAD, iCMP) than acute post-MI inflammation.
Conclusions:
- The NLRP3 inflammasome is a key therapeutic target in ischemic heart disease.
- Immunomodulation offers potential benefits across the IHD spectrum, with varying efficacy.
- Further research is needed to address challenges in modulating acute myocardial inflammation.
Related Concept Videos
01:26Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
371
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
371
01:25Antianginal Drugs: Calcium Channel Blockers and Ranolazine
441
Angina pectoris, a primary symptom of ischemic heart disease, requires careful pharmacological interventions. In this context, calcium channel blockers (CCBs) and ranolazine have emerged as crucial pharmacotherapeutic agents, providing deep insights into the complexities of angina management.
CCBs, a diverse class that includes dihydropyridines (nifedipine) and diphenylalkylamines (verapamil and diltiazem), exert their effect by blocking calcium channels in cardiac and smooth muscle cells. This...
CCBs, a diverse class that includes dihydropyridines (nifedipine) and diphenylalkylamines (verapamil and diltiazem), exert their effect by blocking calcium channels in cardiac and smooth muscle cells. This...
441
01:16Antianginal Drugs: Nitrates and β-Blockers
502
In cardiovascular health, antianginal drugs combat angina pectoris — a condition marked by chest pain owing to diminished blood flow to the heart.
Organic nitrates, such as nitroglycerin, play a pivotal role. Once metabolized, they liberate nitric oxide, a molecular marvel. Nitric oxide triggers guanylyl cyclase and augments cGMP production. This biochemical cascade orchestrates the relaxation of vascular smooth muscles, ushering in vasodilation and enhancing coronary blood flow....
Organic nitrates, such as nitroglycerin, play a pivotal role. Once metabolized, they liberate nitric oxide, a molecular marvel. Nitric oxide triggers guanylyl cyclase and augments cGMP production. This biochemical cascade orchestrates the relaxation of vascular smooth muscles, ushering in vasodilation and enhancing coronary blood flow....
502
01:17Ischemic Heart Disease: Overview
1.1K
Ischemic heart disease occurs when the heart's blood supply dwindles, causing an ominous lack of oxygen and nutrients. This deficiency, stemming from reduced or obstructed blood flow, spells danger, leading to heart muscle damage and dysfunction.
Atherosclerosis, the primary malefactor, orchestrates this dangerous condition. It manifests as the accumulation of fatty deposits, akin to insidious plaques, within arterial walls. As time elapses, these plaques metamorphose, hardening and...
Atherosclerosis, the primary malefactor, orchestrates this dangerous condition. It manifests as the accumulation of fatty deposits, akin to insidious plaques, within arterial walls. As time elapses, these plaques metamorphose, hardening and...
1.1K
01:29Inflammatory Bowel Disease IV: Pharmacological Management
95
Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...
Pharmacologic...
95
01:21Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids
92
Glucocorticoids, a class of anti-inflammatory drugs, are pivotal in treating moderate to severe Crohn's disease by inducing remission. They exhibit their anti-inflammatory action by inhibiting the production of inflammatory cytokines such as tumor necrosis factor (TNF)-α, interleukin (IL)-1, and chemokines like IL-8. In addition, they reduce the expression of inflammatory cell adhesion molecules and inhibit gene transcription of nitric oxide synthase, phospholipase A2, cyclooxygenase-2...
92